Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin + Sintilimab + CCRT in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT07459296Phase 3Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Mar 2026
- Primary completion
- Apr 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of becotatug vedotin, sintilimab in nasopharyngeal carcinoma (NPC), sponsored by The First Affiliated Hospital of Guangxi Medical University. Started Mar 2026; status: recruiting.
02
Drugs
becotatug vedotinsintilimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07459296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07459296.